POMPANO BEACH, FLORIDA., Aug. 16, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused...
Webinar to be held Thursday, August 25th @ 11:00am EDTACTON, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc....
Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2...
Established Homebuilder to Purchase Approximately 121 Acres in Gainesville, Georgia, for Residential Development Proceeds from Sale to Strengthen Societal CDMO’s...
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
LA JOLLA, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE)...
Revenue in USD Revenue In USD Adjusted EBITDA & Operating Income (Loss) in USD $ Adjusted EBITDA & Operating Income...
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:...
Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approvalGENEVA, Switzerland and NEWTON, Mass.,...
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the...
Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful...
BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...
Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data...
FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
Expects interim data by early 2024MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage...
Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial Results for the First Half...
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range...
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated...
Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis patientsSAN DIEGO, Aug. 11, 2022 (GLOBE...